Tens of thousands of Kaiser Permanente workers in California and Hawaii have gone on strike, demanding safer staffing levels ...

Insurers are cutting coverage for costly GLP-1 weight loss drugs, sparking backlash from advocates who say they're vital for ...

Experts warn that the Trump administration’s new $100,000 fee for H-1B visa applications could worsen healthcare’s workforce ...

Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.

Novo Nordisk is acquiring Akero Therapeutics for drug candidate efruxifermin, which executive say could be first and best in ...

Nearly half of healthcare executives plan to leave their organizations within the next year, according to a recent survey. Such significant turnover puts healthcare organizations at risk for ...

DUOS, a technology-enabled service provider, has raised $130 million to expand its platform to more health plans across the country, it announced on Thursday. The Minneapolis-based company supports ...

Market conditions continue to pose challenges for startups trying to raise money. Some of these companies might be a fit for Sanofi’s corporate venture capital arm, which the pharmaceutical giant has ...

Genmab’s growth and pipeline diversification strategy is picking up another piece through the acquisition of Merus in an $8 billion deal focused on a late-stage drug candidate projected to become a ...

Pfizer’s internal obesity drug R&D stumbled, but the pharmaceutical giant is leaping ahead in this field through the multi-billion dollar acquisition of Metsera, a clinical-stage company whose ...

Digital health funding is holding steady — venture capital is flowing, IPOs are reappearing, and megarounds are back in force. Startups in this space have raised $9.9 billion throughout the first ...